TARA FY2025 EPS Forecast Reduced by Cantor Fitzgerald

Protara Therapeutics, Inc. (NASDAQ:TARA) – Stock analysts at Cantor Fitzgerald dropped their FY2025 EPS estimates for Protara Therapeutics in a research note issued on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($1.71) per share for the year, down from their prior estimate of ($1.62). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Several other equities research analysts also recently commented on the stock. Lifesci Capital began coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 target price on the stock. Guggenheim reaffirmed a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Thursday, March 6th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Protara Therapeutics has an average rating of “Buy” and a consensus target price of $22.50.

Protara Therapeutics Trading Up 2.2 %

Shares of TARA stock opened at $4.70 on Monday. The business’s 50-day moving average price is $4.28 and its 200-day moving average price is $3.60. Protara Therapeutics has a 12 month low of $1.60 and a 12 month high of $10.48. The firm has a market capitalization of $172.80 million, a price-to-earnings ratio of -1.67 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TARA. Janus Henderson Group PLC bought a new position in Protara Therapeutics during the fourth quarter worth $11,938,000. Adage Capital Partners GP L.L.C. acquired a new stake in Protara Therapeutics during the 4th quarter worth about $11,880,000. Toronto Dominion Bank acquired a new stake in Protara Therapeutics during the 4th quarter worth about $11,030,000. Blackstone Inc. bought a new position in shares of Protara Therapeutics in the 4th quarter worth about $8,870,000. Finally, RA Capital Management L.P. lifted its stake in shares of Protara Therapeutics by 78.9% in the 4th quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock valued at $17,952,000 after purchasing an additional 1,500,000 shares during the period. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.